#Canada #Laval #Spektus Pharma #GEBRO Holding #ActraFlex

Spektus Pharma and GEBRO Holding Announce Global Commercialization Partnership for ActraFlex®

In a significant development for pain management treatments, Spektus Pharma Inc. and GEBRO Holding GmbH have formed a strategic partnership aimed at the global commercialization of ActraFlex®, a twice-daily extended-release formulation that pairs tramadol with paracetamol. This innovative product leverages Spektus' proprietary AmyloFlex® drug-delivery technology, combined with GEBRO's established Diliban® brand.

ActraFlex® is designed to offer sustained pharmacological effects through its unique formulation, which enables consistent drug release and enhances patient convenience with a dosage regimen that requires administration only twice a day. This partnership plays a vital role in expanding the commercial reach of ActraFlex®, especially in Europe, where GEBRO has already established a strong presence with its Diliban® product line.

Commercialization Strategy and Market Approach

Under this newly formed partnership, GEBRO will oversee the commercialization and distribution of ActraFlex® across Europe, starting with Spain, where their Diliban® line enjoys considerable market strength. Meanwhile, Spektus Pharma will take the reins in the Americas along with selected African and Asian markets, using its robust network of regional pharmaceutical partners to facilitate smooth market entry and expansion.

Zarvaan Merchant, the CEO of Spektus Pharma, praised the collaboration, noting that GEBRO's expertise in pain management, coupled with the innovative technology behind ActraFlex®, positions them uniquely in the global market. “Our partnership with GEBRO highlights the potential of Spektus' proprietary AmyloFlex® technology to create differentiated specialty medicines from established products and brands,” Merchant said.

Christian Kollenz, managing director of GEBRO, echoed similar sentiments, stressing the complementary strengths of both companies in driving the global success of ActraFlex®. The proven success of Diliban® in the European market provides a solid foundation on which to build this new product. The combination of both firms' strengths is predicted to initiate rapid regulatory approvals and subsequent commercialization efforts across their respective territories.

Background of the Companies

Spektus Pharma is known for its focus on developing specialized pharmaceutical products through advanced drug-delivery technologies. The company seeks to address unmet medical needs by improving existing therapies and offering new solutions. With an established distribution network across North America and Europe, Spektus is poised to make a significant impact with ActraFlex®.

On the other hand, GEBRO Holding is well-regarded for its extensive experience in the pharmaceutical market, especially in developing products targeted at pain management and rheumatoid arthritis. Based in Fieberbrunn, Austria, GEBRO’s stronghold in Europe provides a strategic benefit for the partnership, allowing for a swift rollout of ActraFlex® in key markets.

Future Implications

The collaboration on ActraFlex® represents more than just a business venture; it embodies a commitment to enhancing the quality of life for patients suffering from chronic pain through innovative solutions. The financial terms of the agreement have not been disclosed, but the synergy between Spektus and GEBRO shows promising prospects for bringing effective pain management solutions to a broader audience.

As the companies gear up for regulatory discussions and market strategies, the healthcare community and patients alike will be watching closely for updates on ActraFlex®'s launch and subsequent performance in the competitive pain management sector.

This partnership marks a new chapter in the quest for effective and user-friendly pain relief treatments, underscoring the potential that strategic collaborations hold for improving healthcare outcomes on a global scale.